## CIA Client Video Conference

August 2020




## Outline

- 1. General Market Overview
  - 2. Election Update
  - 3. COVID-19 Update










Source: S&P. Dow Jones, Bloomberg


© 2020 Bianco Research, L.L.C. All Rights Reserved https://www.biancoresearch.com/  Dividend Growers and Payers beat every other category in returns, sharpe ratio, StD. Non-paying stocks only beat cutters. (*Data back to 1972*)




Source: Ned Davis Research










#### Hospitalizations Are Spiking But Less Serious ...






# U.S. COVID-19 Deaths Per Day






### Ultimately, We Need A Vaccine (There's Hope!)









There are currently	These fall into	At this time,
197	9	18
vaccines in development for COVID-19.	different product categories / platforms.	vaccines are in one of four phases of clinical testing.

# Leading Candidates

FARTHEST ALONG* CLINICAL		
	Univ. of Oxford/AstraZeneca	PHASE II/III
	Wuhan Inst./Sinopharm	II
	CanSino Biologics	II
	Moderna	II
	Inst. of Medical Biology	II
	Sinovac/Instituto Butantan	II
	Beijing Inst./Sinopharm	II
	BioNTech/Fosun/Pfizer	I/II
	Imperial College London	I/II
	Novavax	I/II
*Ranked by entry into latest phase of development. Clinical phases move when it is publicly reported that the product has been dosed in a trial.		

<sup>\*</sup>Source: Milken Institute

#### Disclaimer

This information is provided to you as a resource for informational purposes only. Information presented herein is provided to you as a guideline for general information and might not be applicable to your individual situation. Investing involves risk, including the possible loss of principal. There is no guarantee offered that investment return, yield, or performance will be achieved. There will be periods of performance fluctuations, including periods of negative returns. Past performance is not indicative of future results when considering any investment vehicle. This information is being presented without consideration of the investment objectives, risk tolerance, or financial circumstances of any specific investor and might not be suitable for all investors. As always, talk to your investment advisor about your specific situation and/or to notify us should any changes arise in your financial situation or investment objective.